Home Newsfeeds HC Wainwright & Co. Maintains Neutral on Bionomics

HC Wainwright & Co. Maintains Neutral on Bionomics

HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.

byBenzinga Newsdesk

March 9, 2023

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.

Tesla, GM, Ford Among Automakers Hit As NHTSA Targets 52M Faulty Airbag Inflators

By Anan Ashraf

September 6, 3:02 AM

Inflators affected by the initial decision include 41 million inflators manufactured by ARC and the nearly 11 million manufactured by Delphi.

ALV

‘Saudi Crude Exports Jump to Highest in More Than Two Years’ -Bloomberg

By Benzinga Newsdesk

August 1, 9:20 AM

https://www.bloomberg.com/news/articles/2022-08-01/saudi-crude-exports-jump-to-highest-in-more-than-two-years Saudi Arabia’s crude exports soared in July to the highest level since April 2020 amid international

USO

e2e Pharma Expanding Manufacturing Facility, Offering End-To-End Co-Pack Services For CBD And Non-CBD Brands

By Vuk Zdinjak

July 19, 11:41 AM

e2e Pharma, a private label end-to-end manufacturer for CBD and non-CBD branded topicals and ingestibles that are sold direct to consumers online and through nationwide retail chains, is expanding the company’s fully operational, 30,000-square-foot manufacturing facility with four clean rooms

Events
News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

By Charles Gross

June 2, 6:47 AM

BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX

HC Wainwright & Co. Maintains Neutral on Bionomics

Related Posts

Tesla, GM, Ford Among Automakers Hit As NHTSA Targets 52M Faulty Airbag Inflators

‘Saudi Crude Exports Jump to Highest in More Than Two Years’ -Bloomberg

e2e Pharma Expanding Manufacturing Facility, Offering End-To-End Co-Pack Services For CBD And Non-CBD Brands

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO